MedTrace Logo

Marker Driven Selection of Patients for Prostate Biopsy and Management

NCT04240327 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 289

Last updated 2025-06-05

No results posted yet for this study

Summary

The purpose of this research study is to determine if the interpretation of multiparametric MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of blood and urine biomarkers is more effective at detecting prostate cancer than standard of care interpretation of mpMRI with the Prostate Imaging Reporting and Data System (PIRADS).

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Miami

    lead OTHER

Principal Investigators

  • Sanoj Punnen, MD, MAS · University of Miami

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2027-06-01
Completion
2027-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04240327 on ClinicalTrials.gov